SUMMARY
Long COVID presents a complex and multi-systemic disease that poses a significant global public health challenge. Symptoms can vary widely, ranging from asymptomatic to severe, making the condition challenging to diagnose and manage effectively. Furthermore, identifying appropriate phenotypes in genome-wide association studies of COVID-19 remains unresolved. This study aimed to address these challenges by analyzing 220 deep-phenotype genome-wide association data sets (159 diseases, 38 biomarkers and 23 medication usage) from BioBank Japan (BBJ) (n=179,000), UK Biobank and FinnGen (n=628,000) to investigate pleiotropic effects of known COVID-19 risk associated single nucleotide variants. Our findings reveal 32 different phenotypes that share the common genetic risk factors with COVID-19 (p < 7.6×10−11), including two diseases (myocardial infarction and type 2 diabetes), 26 biomarkers with seven categories (blood cell, metabolic, liver-related, kidney-related, protein, inflammatory and anthropometric), and four medications (antithrombotic agents, HMG CoA reductase inhibitors, thyroid preparations and anilides). As long COVID continues to coexist with humans, our results highlight the need for targeted screening to support specific vulnerable populations to improve disease prevention and healthcare delivery.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the Japan China Sasakawa Medical Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Single nucleotide variants (SNPs) that represent either susceptibility to SARS-CoV-2 infection or risk of severe COVID-19 disease can be available from he COVID-19 host genetics initiative (https://www.covid19hg.org/). The genotype and phenotype data can be accessed through application at BioBank Japan PheWeb (https://pheweb.jp/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
